ketoconazole has been researched along with Neoplasm Metastasis in 24 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results indicate that ketoconazole significantly reduced hepatic metastases from the human pancreatic carcinoma RWP-2 in the nude mouse model, and inhibited thromboxane B2 formation, potentiating a concomitant redirection of platelet endoperoxide metabolism into PGD2, PGE2, and 6-keto-F1a." | 3.71 | The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis. ( Krambovitis, E; Tsatsakis, AM; Tzanakakis, GN; Vezeridis, MP, 2002) |
| "Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy." | 2.73 | Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. ( Brown, MA; Do, KA; Logothetis, CJ; Millikan, RE; Moomey, B; Pagliaro, LC; Wen, S, 2008) |
| "Fixed dosing was found to be feasible, without increased variability of clearance or neutrophil toxicity compared to BSA-based dosing." | 2.73 | A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. ( Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP, 2008) |
| "Ketoconazole action dosed as 400-600 g per day was studied in 12 patients with prostatic metastasizing carcinoma." | 2.67 | [Results of a clinical trial of ketoconazole in metastatic prostatic carcinoma]. ( Morávek, P; Zita, K, 1991) |
| "Almost all patients with prostatic cancer will eventually escape the control of the first-line endocrine therapy and relapse." | 2.38 | Management of relapsing disease in prostate cancer. ( Denis, L; Mahler, C, 1992) |
| "Prednisone use was associated with a reduced risk of progression on docetaxel in the propensity score-weighted multivariable Cox model (P=0." | 1.43 | The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. ( Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA, 2016) |
| "Invasion and metastasis are responsible for 90% of cancer-related mortality." | 1.42 | 4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model. ( Bracke, ME; De Ryck, T; Katritzky, AR; Patronov, A; Roman, BI; Slavov, SH; Stevens, CV; Vanhoecke, BW, 2015) |
| "Ketoconazole (KT) is a less potent CYP17 inhibitor previously widely used in mCRPC." | 1.40 | Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. ( Alimohamed, N; Atenafu, EG; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Seah, JA; Sridhar, SS; Tannock, IF; Templeton, AJ; Vera-Badillo, FE, 2014) |
| "Ketoconazole can suppress androgen production and has a beneficial role in the hormonal therapy of patients with prostate cancer who have not undergone orchiectomy." | 1.27 | High-dose ketoconazole therapy in patients with metastatic prostate cancer. ( Al-Sarraf, M; Decker, DA; Kresge, C; Subramanian, MG; Tapazoglou, E, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (29.17) | 18.7374 |
| 1990's | 5 (20.83) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 8 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roman, BI | 1 |
| De Ryck, T | 1 |
| Patronov, A | 1 |
| Slavov, SH | 1 |
| Vanhoecke, BW | 1 |
| Katritzky, AR | 1 |
| Bracke, ME | 1 |
| Stevens, CV | 1 |
| Almassi, N | 1 |
| Reichard, C | 1 |
| Li, J | 1 |
| Russell, C | 1 |
| Perry, J | 1 |
| Ryan, CJ | 2 |
| Friedlander, T | 1 |
| Sharifi, N | 1 |
| Leibowitz-Amit, R | 1 |
| Seah, JA | 1 |
| Atenafu, EG | 1 |
| Templeton, AJ | 1 |
| Vera-Badillo, FE | 1 |
| Alimohamed, N | 1 |
| Knox, JJ | 1 |
| Tannock, IF | 1 |
| Sridhar, SS | 1 |
| Joshua, AM | 1 |
| Kim, W | 1 |
| Zhang, L | 1 |
| Wilton, JH | 1 |
| Fetterly, G | 1 |
| Mohler, JL | 1 |
| Weinberg, V | 1 |
| Morse, A | 1 |
| Szmulewitz, RZ | 1 |
| Friedlander, TW | 1 |
| Fong, L | 1 |
| Lin, AM | 1 |
| Harzstark, AL | 1 |
| Molina, A | 1 |
| Small, EJ | 2 |
| Teply, BA | 1 |
| Luber, B | 1 |
| Denmeade, SR | 1 |
| Antonarakis, ES | 1 |
| Millikan, RE | 1 |
| Wen, S | 1 |
| Pagliaro, LC | 1 |
| Brown, MA | 1 |
| Moomey, B | 1 |
| Do, KA | 1 |
| Logothetis, CJ | 1 |
| Figg, WD | 1 |
| Woo, S | 1 |
| Zhu, W | 1 |
| Chen, X | 1 |
| Ajiboye, AS | 1 |
| Steinberg, SM | 1 |
| Price, DK | 1 |
| Wright, JJ | 1 |
| Parnes, HL | 1 |
| Arlen, PM | 1 |
| Gulley, JL | 1 |
| Dahut, WL | 1 |
| Pond, GR | 1 |
| Armstrong, AJ | 1 |
| Galsky, MD | 1 |
| Wood, BA | 1 |
| Leopold, L | 1 |
| Sonpavde, G | 1 |
| Lin, GW | 1 |
| Yao, XD | 1 |
| Ye, DW | 1 |
| Zhu, Y | 1 |
| Zhang, SL | 1 |
| Dai, B | 1 |
| Zhang, HL | 1 |
| Shen, YJ | 1 |
| Ma, CG | 1 |
| Tzanakakis, GN | 1 |
| Krambovitis, E | 1 |
| Tsatsakis, AM | 1 |
| Vezeridis, MP | 1 |
| Yong, WP | 1 |
| Wang, LZ | 1 |
| Tham, LS | 1 |
| Wong, CI | 1 |
| Lee, SC | 1 |
| Soo, R | 1 |
| Sukri, N | 1 |
| Lee, HS | 1 |
| Goh, BC | 1 |
| Spors, S | 1 |
| Möller, A | 1 |
| Baron, AD | 1 |
| Fippin, L | 1 |
| Apodaca, D | 1 |
| Bare, RL | 1 |
| Torti, FM | 1 |
| Rickman, T | 1 |
| Garmany, R | 1 |
| Doherty, T | 1 |
| Benson, D | 1 |
| Okusa, MD | 1 |
| Mahler, C | 1 |
| Denis, L | 1 |
| Morávek, P | 1 |
| Zita, K | 1 |
| Lowe, FC | 1 |
| Bamberger, MH | 1 |
| Tapazoglou, E | 1 |
| Subramanian, MG | 1 |
| Al-Sarraf, M | 1 |
| Kresge, C | 1 |
| Decker, DA | 1 |
| Oelschläger, H | 1 |
| Rothley, D | 1 |
| Dunzendorfer, U | 1 |
| Eichenberger, T | 1 |
| Trachtenberg, J | 1 |
| Debruyne, FM | 1 |
| Witjes, FA | 1 |
| Castillo Cádiz, O | 1 |
| Martínez Sanz, P | 1 |
| Dubost, JJ | 1 |
| Sauvezie, B | 1 |
| Ristori, JM | 1 |
| Thevenet, JP | 1 |
| Rampon, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Trial of Androgen Ablation Alone vs. Chemo/Hormonal Therapy as Initial Treatment of Unresectable/Metastatic Adenocarcinoma of the Prostate[NCT00002855] | Phase 3 | 306 participants (Actual) | Interventional | 1996-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ketoconazole and Neoplasm Metastasis
| Article | Year |
|---|---|
Endocrine therapy of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Antineoplasti | 1998 |
Management of relapsing disease in prostate cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Estrogens | 1992 |
[New hormonal treatments of metastatic prostatic cancer. Review of the literature].
Topics: Aminoglutethimide; Androgen Antagonists; Animals; Antineoplastic Agents; Combined Modality Therapy; | 1985 |
7 trials available for ketoconazole and Neoplasm Metastasis
| Article | Year |
|---|---|
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgens; Androstenes; Humans; Ketoconazole; Male; Mi | 2014 |
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Ag | 2008 |
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Drug Interacti | 2010 |
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Hu | 2013 |
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-R | 2008 |
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Hy | 1997 |
[Results of a clinical trial of ketoconazole in metastatic prostatic carcinoma].
Topics: Aged; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms | 1991 |
14 other studies available for ketoconazole and Neoplasm Metastasis
| Article | Year |
|---|---|
4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Cell Movement; Ce | 2015 |
HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Topics: Aged; Alleles; Androgen Antagonists; Biomarkers, Tumor; Gain of Function Mutation; Gene Expression R | 2018 |
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free S | 2016 |
The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?
Topics: Aged; Humans; Ketoconazole; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms | 2012 |
The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis.
Topics: 6-Ketoprostaglandin F1 alpha; Adenocarcinoma; Animals; Antineoplastic Agents; Dinoprostone; Humans; | 2002 |
[Malignant hemangiopericytoma. Candida meningitis under ketoconazole therapy].
Topics: Adult; Candidiasis; Female; Hemangiopericytoma; Humans; Ketoconazole; Leukopenia; Meningitis; Neopla | 1983 |
Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma.
Topics: ACTH Syndrome, Ectopic; Adenocarcinoma; Adrenocorticotropic Hormone; Aged; Alkalosis; Comorbidity; C | 2001 |
Indications for use of ketoconazole in management of metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Contraindications; Estrogens; Humans; Ketoconazol | 1990 |
High-dose ketoconazole therapy in patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androstenedione; Combined Modality Therapy; Dehydroepiandrosterone; Dexamethas | 1986 |
[Drug therapy of metastasizing prostate carcinoma with special reference to the bioavailability of fosfestrol after oral administration].
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents; Biological Availability; Bi | 1988 |
Effects of high-dose ketoconazole in patients with androgen-independent prostatic cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Humans; Ketoconazole; Male; Middle | 1988 |
Ketoconazole high dose (H.D.) in the management of hormonally pretreated patients with progressive metastatic prostate cancer.
Topics: Estrogens; Humans; Hydrocortisone; Ketoconazole; Male; Neoplasm Metastasis; Orchiectomy; Prostatic N | 1987 |
[Ketoconazole in the treatment of advanced cancer of the prostate: experience with 14 patients].
Topics: Acid Phosphatase; Aged; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neop | 1985 |